107 related articles for article (PubMed ID: 18569639)
1. Leukemic cells with increased telomerase activity exhibit resistance to imatinib.
Yamada O; Kawauchi K; Akiyama M; Ozaki K; Motoji T; Adachi T; Aikawa E
Leuk Lymphoma; 2008 Jun; 49(6):1168-77. PubMed ID: 18569639
[TBL] [Abstract][Full Text] [Related]
2. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
White DL
Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
[No Abstract] [Full Text] [Related]
3. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
4. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
6. hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications.
Deville L; Hillion J; Pendino F; Samy M; Nguyen E; Ségal-Bendirdjian E
Mol Cancer Ther; 2011 May; 10(5):711-9. PubMed ID: 21364010
[TBL] [Abstract][Full Text] [Related]
7. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
8. Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Varma N; Anand MS; Varma S; Juneja SS
Leuk Lymphoma; 2011 Apr; 52(4):687-93. PubMed ID: 21314483
[TBL] [Abstract][Full Text] [Related]
9. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
11. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
12. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
13. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
14. Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Kuo TC; Chavarria-Smith JE; Huang D; Schlissel MS
Mol Cell Biol; 2011 Jul; 31(13):2566-76. PubMed ID: 21536647
[TBL] [Abstract][Full Text] [Related]
15. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
16. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Larghero J; Leguay T; Mourah S; Madelaine-Chambrin I; Taksin AL; Raffoux E; Bastie JN; Degos L; Berthaud P; Marolleau JP; Calvo F; Chomienne C; Mahon FX; Rousselot P
Biochem Pharmacol; 2003 Nov; 66(10):1907-13. PubMed ID: 14599548
[TBL] [Abstract][Full Text] [Related]
17. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells.
Tauchi T; Nakajima A; Sashida G; Shimamoto T; Ohyashiki JH; Abe K; Yamamoto K; Ohyashiki K
Clin Cancer Res; 2002 Nov; 8(11):3341-7. PubMed ID: 12429620
[TBL] [Abstract][Full Text] [Related]
19. hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
Campbell LJ; Fidler C; Eagleton H; Peniket A; Kusec R; Gal S; Littlewood TJ; Wainscoat JS; Boultwood J
Leukemia; 2006 Apr; 20(4):671-9. PubMed ID: 16498395
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Illmer T; Schaich M; Platzbecker U; Freiberg-Richter J; Oelschlägel U; von Bonin M; Pursche S; Bergemann T; Ehninger G; Schleyer E
Leukemia; 2004 Mar; 18(3):401-8. PubMed ID: 14724652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]